TRENDING :  Market Movers  |  Top 50   SPY (0.23%)    TSLA (-2.49%)    CANF (1.36%)    BYND (-2.96%)    BTCUSD (%)    ONCS (-3.12%)    AMZN (0.43%)    TVIX (-4.25%)    VXX (-2.07%)    ROKU (6.45%)    ACAD (2.45%)    OIH (-1.43%)    MCHP (-1.44%)    MAXR (-13.79%)    IRBT (0.03%)    IP (-0.24%)    INTC (0.09%)    GDX (0.64%)    FTNT (0.33%)    ECOR (-4.53%)    DNR (3.23%)    DIS (0.05%)    DFRG (2.06%)    CMG (-0.69%)    BIOC (9.74%)

 AFMD - Affimed N.V.

$3.10 [0.11][3.34%]

Next Earnings

8/7/2019

BMO

Recommend
Trade Idea »



ANALYST RATINGS

Quarterly Rating Chart
Rating

1


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $8.00
Low $8.00
Average $8.00
Current $3.10

CompanyAnalyst NamePT ActionActionRatingTargetDate
SVB LeerinkAnnouncesInitiates Coverage OnStrong Buy$8.0003/28/19
*Last 90 days

OPEN RECOMMENDATIONS

Stocks
Service NameTrader NamePosition TypeTarget %Target PriceTarget Date Issue Date
Value InvestingFlying ColorsSubscribe1,700.00 %Subscribe07/11/1909/11/18View
Value InvestingFlying ColorsSubscribe1,042.86 %Subscribe09/05/1909/05/18View
Value InvestingFlying ColorsSubscribe1,138.94 %Subscribe09/04/1909/04/18View


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $AFMD

RECENT SUCCESSFUL RECOMMENDATIONS

SymbolService NamePosition TypeIssuePrice Target PriceClose Date% Return Comments
AFMDLetsGrow - MoversBuy Long$1.70$1.8501/24/178.82 %CommentsView

TRENDING ARTICLES



Affimed (AFMD) Earnings and Sales Exceed Estimates in Q1

05/23/19
Affimed N V AFMD reported earnings per share of 3 cents in the first quarter of 2019 against a loss of 18 cents in the year ago quarter Earnings also surpassed the Zacks Consensus Estimate of a loss of 16 cents The revenues were 13 million million 160 in the first quarter up from 1

Affimed N.V. (AFMD) Q1 2019 Earnings Call Transcript

05/22/19
Image source The Motley Fool Affimed N V NASDAQ AFMD Q1 160 2019 Earnings Call May 22 2019 8 30 a m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks Operator Good day and

Affirmed Therapeutics (AFMD) Beats Q1 Earnings and Revenue Estimates

05/22/19
Affirmed Therapeutics AFMD came out with quarterly earnings of 0 03 per share beating the Zacks Consensus Estimate of a loss of 0 16 per share This compares to loss of 0 18 per share a year ago These figures are adjusted for non recurring items This quarterly report represents an

Health Care Sector Update for 05/22/2019: OBLN, CODX, AFMD, JNJ, PFE, ABT, MRK, AMGN

05/22/19
Top Health Care Stocks Top Health Care Stocks JNJ 0 09 JNJ 0 09 PFE 0 12 PFE 0 12 ABT 0 14 ABT 0 14 MRK 0 31 MRK 0 31 AMGN FlatAMGN Flat Leading health care stocks were mixed in Wednesday s pre market trading Leading health care stocks were mixed in Wednesday spre

Pre-Market Earnings Report for May 22, 2019 : LOW, TGT, CM, ADI, VFC, AAP, GOGL, PLAB, ECC, AFMD

05/21/19
The following companies are expected to repor t earnings prior to market open on 05 22 2019 Visit our Earnings Calendar for a full list of expected earnings releases Lowe s Companies Inc LOW is reporting for the quarter ending April 30 2019

Affirmed Therapeutics (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

05/14/19
Wall Street expects a year over year increase in earnings on higher revenues when Affirmed Therapeutics AFMD reports results for the quarter ended March 2019 While this widely known consensus outlook is important in gauging the company s earnings picture a powerful factor that could impact

What's in Store for Affimed (AFMD) This Earnings Season?

05/13/19
Investors will likely focus on the progress of Affimed N V s AFMD lead pipeline candidate AFM13 on the company s first quarter earnings call In the las t report ed quarter the company delivered a positive earnings surprise of 200 00 The company has a mixed track record It

Affirmed Therapeutics (AFMD) Moves to Buy: Rationale Behind the Upgrade

04/30/19
Affirmed Therapeutics AFMD could be a solid choice for investors given its recent upgrade to a Zacks Rank 2 Buy An upward trend in earnings estimates one of the most powerful forces impacting stock prices has triggered this rating change The sole determinant of the Zacks rating is